Skip to main content
SpringerLink
Log in

Vedolizumab good value in ulcerative colitis in Japan

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Takeda Pharmaceuticals Company Ltd. in Tokyo, Japan.

Reference

  • Hernandez L, et al. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naive Patients with Moderate-to-Severe Ulcerative Colitis in Japan. PharmacoEconomics : 24 Sep 2019. Available from: URL: https://doi.org/10.1007/s40273-019-00841-1

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vedolizumab good value in ulcerative colitis in Japan. PharmacoEcon Outcomes News 838, 32 (2019). https://doi.org/10.1007/s40274-019-6277-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6277-8

Search

Navigation